European Journal of Haematology

Article	Citations
Changing patterns in the epidemiology of β‐thalassemia	118
COVID‐19 vaccine‐associated immune thrombosis and thrombocytopenia (VITT): Diagnostic and therapeutic recommendations for a new syndrome	101
COVID‐19 coagulopathy: An in‐depth analysis of the coagulation system	90
The vaso‐occlusive pain crisis in sickle cell disease: Definition, pathophysiology, and management	89
Haematological manifestations of COVID‐19: From cytopenia to coagulopathy	69
Clinical course and risk factors for mortality from COVID‐19 in patients with haematological malignancies	68
The hematologic consequences of obesity	66
Association of anticoagulation dose and survival in hospitalized COVID‐19 patients: A retrospective propensity score‐weighted analysis	63
COVID‐19 infection and treatment with hydroxychloroquine cause severe haemolysis crisis in a patient with glucose‐6‐phosphate dehydrogenase deficiency	42
Blinatumomab in pediatric patients with relapsed/refractory B‐cell precursor acute lymphoblastic leukemia	38
Pairing MCL‐1 inhibition with venetoclax improves therapeutic efficiency of BH3‐mimetics in AML	36
Prevalence of pyruvate kinase deficiency: A systematic literature review	35
Cellular immune response to acute exercise: Comparison of endurance and resistance exercise	34
The changing epidemiology of the ageing thalassaemia populations: A position statement of the Thalassaemia International Federation	32
Real‐world outcomes for 205 patients with chronic lymphocytic leukemia treated with ibrutinib	32
The incidence of thrombocytopenia in adult patients receiving chemotherapy for solid tumors or hematologic malignancies	31
Treating secondary antibody deficiency in patients with haematological malignancy: European expert consensus	30
Ruxolitinib as adjunctive therapy for secondary hemophagocytic lymphohistiocytosis: A case series	28
Cost‐effectiveness of Anti‐CD19 chimeric antigen receptor T‐Cell therapy in pediatric relapsed/refractory B‐cell acute lymphoblastic leukemia. A societal view	28
Anticoagulation strategies in extracorporeal circulatory devices in adult populations	27
Patient outcomes in light chain (AL) amyloidosis: The clock is ticking from symptoms to diagnosis	26
COVID‐19 and thalassaemia: A position statement of the Thalassaemia International Federation	25
Quality of life in patients of chronic lymphocytic leukemia using the EORTC QLQ‐C30 and QLQ‐CLL17 questionnaire	25
CDK 4/6 inhibitors are associated with a high incidence of thrombotic events in women with breast cancer in real‐world practice	25
The incidence, complications, and treatment of iron deficiency in pregnancy	24

One‐year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab	23
Regional outcomes of severe acute respiratory syndrome coronavirus 2 infection in hospitalised patients with haematological malignancy	22
Current understanding and future implications of sepsis‐induced thrombocytopenia	22
The role of ROTEM variables based on clot elasticity and platelet component in predicting bleeding risk in thrombocytopenic critically ill neonates	22
Fecal microbiota transfer for refractory intestinal graft‐versus‐host disease — Experience from two German tertiary centers	21
Primary pancreatic lymphoma: Clinical presentation, diagnosis, treatment, and outcome	21
SARS‐CoV‐2 infection among patients with haematological disorders: Severity and one‐month outcome in 66 Danish patients in a nationwide cohort study	21
Prognostic impact and risk factors of cancer‐associated thrombosis events in stage‐IV cancer patients treated with immune checkpoint inhibitors	21
Monitoring treatment response and disease progression in myeloma with circulating cell‐free DNA	20
The incidence and prevalence of patients with paroxysmal nocturnal haemoglobinuria and aplastic anaemia PNH syndrome: A retrospective analysis of the UK’s population‐based haematological malignancy re	19
Targeting both BET and CBP/EP300 proteins with the novel dual inhibitors NEO2734 and NEO1132 leads to anti‐tumor activity in multiple myeloma	19
Effectiveness and safety of apixaban and rivaroxaban for acute venous thromboembolism therapy in patients with extremes in bodyweight	19
Long‐term follow‐up of patients with venous thromboembolism and COVID‐19: Analysis of risk factors for death and major bleeding	19
Review of Vitamin B12 deficiency in pregnancy: a diagnosis not to miss as veganism and vegetarianism become more prevalent	19
Treatment with temozolomide and ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL)	18
Long‐term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2‐year results from two pivotal phase 3 studies	18
Characteristics of peripheral blood differential counts in hospitalized patients with COVID‐19	18
Comorbidities in multiple myeloma and implications on survival: A population‐based study	18
Diagnostic delay and characterization of the clinical prodrome in AL amyloidosis among 1523 US adults diagnosed between 2001 and 2019	18
Sickle cell trait and the potential risk of severe coronavirus disease 2019—A mini‐review	17
Combination of myeloproliferative neoplasm driver gene activation with mutations of splice factor or epigenetic modifier genes increases risk of rapid blastic progression	17
A randomized, double‐blind, single‐dose, three‐arm, parallel group study to determine pharmacokinetic similarity of ABP 959 and eculizumab (Soliris®) in healthy male subjects	17
Favorable COVID‐19 course despite significant comorbidities in a ruxolitinib‐treated patient with primary myelofibrosis	17
The prognostic impact of variant allele frequency (VAF) in TP53 mutant patients with MDS: A systematic review and meta‐analysis	16
Reasons and consequences of COVID‐19 vaccine failure in patients with chronic lymphocytic leukemia	16
Comorbidities and complications in adults with pyruvate kinase deficiency	16
Clinical prevalence and outcome of cardiovascular events in the first 100 days postallogeneic hematopoietic stem cell transplant	16
Outcome of COVID‐19 in multiple myeloma patients in relation to treatment	15
Causes of hypereosinophilia in 100 consecutive patients	15
Clinical predictors of SARS‐CoV‐2 neutralizing antibody titers in COVID‐19 convalescents: Implications for convalescent plasma donor recruitment	15
Emicizumab treatment: Impact on coagulation tests and biological monitoring of haemostasis according to clinical situations (BIMHO group proposals)	14
Validation of the HScore and the HLH‐2004 diagnostic criteria for the diagnosis of hemophagocytic lymphohistiocytosis in a multicenter cohort	14
Janus‐faced course of COVID‐19 infection in patients with hematological malignancies	13
The role of oral iron in the treatment of adults with iron deficiency	13
T cell–mediated autoimmunity in immune thrombocytopenia	13
Acquired aplastic anemia following SARS‐CoV‐2 vaccination	13
Impact of time to diagnosis on Mayo stages, treatment outcome, and survival in patients with AL amyloidosis and cardiac involvement	13
Bone lesions in hairy cell leukemia: Diagnosis and treatment	12
Early report on the severity of COVID‐19 in hematologic patients infected with the SARS‐CoV2 omicron variant	12
Daratumumab for relapsed AL amyloidosis—When cumulative real‐world data precedes clinical trials: A multisite study and systematic literature review	12
Soluble interleukin‐2 receptor (sIL‐2r) level is a limited test for the diagnosis of adult secondary hemophagocytic lymphohistiocytosis	12
Acute myeloid leukemia with inv(3)(q21.3q26.2)/t(3;3)(q21.3;q26.2): Study of 61 patients treated with intensive protocols	12
Impact of body mass index on relapse in children with acute lymphoblastic leukemia treated according to Nordic treatment protocols	12
Role of pre‐transplant MRD level detected by flow cytometry in recipients of allogeneic stem cell transplantation with AML	12
Impact of a comprehensive geriatric assessment on decision‐making in older patients with hematological malignancies	12
The risk of thrombosis in essential thrombocythemia is associated with the type of CALR mutation: A multicentre collaborative study	12
Organ sparing total marrow irradiation compared to total body irradiation prior to allogeneic stem cell transplantation	12
Treatment patterns and clinical outcomes of tyrosine kinase inhibitors in chronic‐phase CML in clinical practice: 3‐year European SIMPLICITY data	11
Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma in the real world	11
Real‐world data on voxelotor to treat patients with sickle cell disease	11

Iron chelation therapy	11
Assessing the risk of thromboembolism in cancer patients receiving immunotherapy	11
A 3′ tRNA‐derived fragment produced by tRNALeuAAG and tRNALeuTAG is associated with poor prognosis in B‐cell chronic lymphocytic leukemia, independently of classical prognostic f	11
Safety of apixaban compared to warfarin in hemodialysis patients: Do antiplatelets make a difference?	10
Clinical efficacy of mogamulizumab for relapsed/refractory aggressive adult T‐cell leukemia/lymphoma: A retrospective analysis	10
Haploidentical transplantation in pediatric non‐malignant diseases: A retrospective analysis on behalf of the Spanish Group for Hematopoietic Transplantation (GETH)	10
Prognostic impact of pretransplant measurable residual disease assessed by peripheral blood WT1‐mRNA expression in patients with AML and MDS	10
Next‐generation sequencing in hypoplastic bone marrow failure: What difference does it make?	10
Recombinant factor VIII Fc for the treatment of haemophilia A	10
The value of screening biopsies in light‐chain (AL) and transthyretin (ATTR) amyloidosis	10
The efficacy and safety of DOACs versus LMWH for cancer‐associated thrombosis: A systematic review and meta‐analysis	10
Cellular and humoral response to the fourth BNT162b2 mRNA COVID‐19 vaccine dose in patients with CLL	10
Impact of performance status on overall survival in patients with relapsed and/or refractory multiple myeloma: Real‐life outcomes of daratumumab treatment	10
Long‐term cardiac, vascular, hypertension, and effusion safety of bosutinib in patients with Philadelphia chromosome–positive leukemia resistant or intolerant to prior therapy	10
Lymph node core needle biopsy for the diagnosis of lymphoproliferative disorders: A word of caution	10
Real‐world treatment patterns and outcomes in non‐transplant newly diagnosed multiple Myeloma in France, Germany, Italy, and the United Kingdom	10
White blood count, D‐dimers, and ferritin levels as predictive factors of pulmonary embolism suspected upon admission in noncritically ill COVID‐19 patients: The French multicenter CLOTVID retrospecti	10
Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: A randomised phase 2 trial by the Nordic Myeloma Study Group	9
MALT‐1 as a novel therapeutic target for adult T‐cell leukemia	9
Outcome data from >10 000 multiple myeloma patients in the Danish and Swedish national registries	9
The burden of illness of patients with paroxysmal nocturnal haemoglobinuria receiving C5 inhibitors in France, Germany and the United Kingdom: Patient‐reported insights on symptoms and qual	9
Dactinomycin in acute myeloid leukemia with NPM1 mutations	9
Doubtful precipitation of hemolysis by hydroxychloroquine in glucose‐6‐phosphate dehydrogenase‐deficient patient with COVID‐19 infection	9
Anti‐thymocyte globulin and post‐transplant cyclophosphamide predisposes to inferior outcome when using cryopreserved stem cell grafts	9
Letter to the Editor: Fine‐needle aspiration cytology and core‐needle biopsy in the diagnosis of lymphadenopathies: Words of endorsement	9
The hemostatic and thrombotic complications of liver disease	9
High levels of immunoglobulin expression predict shorter overall survival in patients with acute myeloid leukemia	9
Principles of care for acquired hemophilia	9
Characteristics and recognition of early infections in patients treated with commercial anti‐CD19 CAR‐T cells	9
Impact of age on the cumulative risk of transformation in patients with chronic myelomonocytic leukaemia	9
Refractory autoimmune cytopenias in pediatric Evans syndrome with underlying systemic immune dysregulation	9
Cumulative exposure to melphalan chemotherapy and subsequent risk of developing acute myeloid leukemia and myelodysplastic syndromes in patients with multiple myeloma	8
Pain and functional disability amongst adults with moderate and severe haemophilia from the Irish personalised approach to the treatment of haemophilia (iPATH) study	8
Anagrelide in Essential Thrombocythemia (ET): Results from 150 patients over 25 years by the “Ph1‐negative Myeloproliferative Neoplasms Latium Group”	8
Combination of brentuximab‐vedotin and ifosfamide, carboplatin, etoposide in relapsed/refractory peripheral T‐cell lymphoma	8
Image‐guided core needle biopsy as the first‐line diagnostic approach in lymphoproliferative disorders—A review of the current literature	8
Late occurrence of progressive multifocal leukoencephalopathy after anti‐CD19 chimeric antigen receptor T‐cell therapy	8
Clonal cytopenia of undetermined significance (CCUS) with dysplasia is enriched for MDS‐type molecular findings compared to CCUS without dysplasia	8
Application of comprehensive geriatric assessment in predicting early mortality among elder patients with B‐cell lymphoma receiving immunochemotherapy	8
VEXAS syndrome: A review of bone marrow aspirate and biopsies reporting myeloid and erythroid precursor vacuolation	8
POEMS syndrome: A multisystem clonal disorder	8
Lymphoid malignancy in common variable immunodeficiency in a single‐center cohort	8
CAR‐T cell therapy for patients with hematological malignancies. A systematic review	8
Lymph node core biopsies reliably permit diagnosis of lymphoproliferative diseases. Real‐World Experience from 554 sequential core biopsies from a single centre	8
Androgens stimulate erythropoiesis through the DNA‐binding activity of the androgen receptor in non‐hematopoietic cells	8
Thromboembolic complications in autoimmune hemolytic anemia: Retrospective study	8
Adverse prognostic impact of regulatory T‐cells in testicular diffuse large B‐cell lymphoma	8
Immune thrombocytopenic purpura secondary to COVID‐19 vaccination: A systematic review	8
Impact of platelets on major thrombosis in patients with a normal white blood cell count in essential thrombocythemia	7
Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high‐risk cytogenetics: IKEMA subgroup analysis	7
Outcomes of relapsed or refractory acute myeloid leukemia patients failing venetoclax‐based salvage therapies	7
Lenalidomide as maintenance treatment for patients with multiple myeloma after autologous stem cell transplantation: A pharmaco‐economic assessment	7
COVID‐19 complicated by parainfluenza co‐infection in a patient with chronic lymphocytic leukemia	7
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide‐pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics	7
Association between red blood cell transfusion dependence and burden in patients with myelodysplastic syndromes: A systematic literature review and meta‐analysis	7
The role of CUDC‐907, a dual phosphoinositide‐3 kinase and histone deacetylase inhibitor, in inhibiting proliferation of adult T‐cell leukemia	7
Carfilzomib, cyclophosphamide, and dexamethasone (KCd) for the treatment of triple‐class relapsed/refractory multiple myeloma (RRMM)	7
Survival trends in elderly myeloma patients	7
Monocenter study on epidemiology, outcomes, and risk factors of infections in recipients of 166 allogeneic stem cell transplantations during 1 year	7
Survival in autoimmune hemolytic anemia remains poor, results from a nationwide cohort with 37 years of follow‐up	7
Pre‐transplant minimal residual disease assessment and transplant‐related factors predict the outcome of acute myeloid leukemia patients undergoing allogeneic stem cell transplantation	7
Clonal haematopoiesis of indeterminate potential and impaired kidney function—A Danish general population study with 11 years follow‐up	7
Matched sibling donor stem cell transplantation for sickle cell disease: Results from the Spanish group for bone marrow transplantation in children	7
Intracranial hemorrhage in newly diagnosed non‐promyelocytic acute myeloid leukemia patients admitted for intensive induction chemotherapy	7
Management of rare inherited bleeding disorders: Proposals of the French Reference Centre on Haemophilia and Rare Coagulation Disorders	7
Impact of infectious comorbidity and overall time of hospitalization in total outpatient management of acute myeloid leukemia patients following venetoclax and hypomethylating agents	7
mRNA COVID‐19 vaccines in patients with chronic lymphocytic leukemia: A systematic review and meta‐analysis	7
A retrospective study of treosulfan versus busulfan‐based conditioning in pediatric patients	6
Direct oral anticoagulants versus warfarin in patients with single antibody‐positive anti‐phospholipid syndrome	6
Higher average chemotherapy dose intensity improves prognosis in patients with aggressive adult T‐cell leukemia/lymphoma	6
Beneficial effects of eculizumab regardless of prior transfusions or bone marrow disease: Results of the International Paroxysmal Nocturnal Hemoglobinuria Registry	6
Clinical benefit of ixazomib plus lenalidomide‐dexamethasone in myeloma patients with non‐canonical NF‐κB pathway activation	6
Treatment horizon in multiple myeloma	6
Progressive multifocal leukoencephalopathy in the context of newer therapies in hematology and review of new treatment strategies	6
c‐MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide‐dexamethasone in myeloma	6
Data‐driven analysis of the kinetics of the JAK2V617F allele burden and blood cell counts during hydroxyurea treatment of patients with polycythemia vera, essential thrombocythemia, and primary	6
Neutralizing antibody responses against SARS‐CoV‐2 in patients with plasma cell disorders who are on active treatment after two doses of mRNA vaccination	6
Oxidative stress, inflammation, blood rheology, and microcirculation in adults with sickle cell disease: Effects of hydroxyurea treatment and impact of sickle cell syndrome	6
Soluble programmed cell death protein 1 (sPD‐1) and the soluble programmed cell death ligands 1 and 2 (sPD‐L1 and sPD‐L2) in lymphoid malignancies	6
Autoimmune disease is associated with a lower risk of progression in monoclonal gammopathy of undetermined significance	6

Prevalence and risk factors for Pulmonary Hypertension associated with chronic Myeloproliferative Neoplasms	6
The management, outcome, and postpartum disease course of 41 pregnancies in 20 women with polycythemia vera	6
Characteristics and potential biomarkers of adult sickle cell patients with chronic pain	6
Molecular pharmacology in complement‐mediated hemolytic disorders	6
Integrin expression and adhesivity to fibronectin in primary acute myeloid leukemia cells: Impact of NPM1 and FLT3 mutations	6
Outcomes of ixazomib/lenalidomide/dexamethasone for multiple myeloma: A multicenter retrospective analysis	6
Use of midostaurin in mixed phenotype acute leukemia with FLT3 mutation: A case series	6
Platelet transfusion and tranexamic acid to prevent bleeding in outpatients with a hematological disease: A Dutch nationwide survey	6
Food‐effect study of nilotinib in chronic myeloid leukaemia (NiFo study): Enabling dose reduction and relief of treatment burden	6
Bleeding complications in bcr‐abl‐negative myeloproliferative neoplasms (MPN): A retrospective single‐center study of 829 MPN patients	6
Efficacy of Helicobater pylori eradication in patients with diffuse large B‐cell lymphoma of the stomach: A systematic review	6
Long‐term outcome in patients with follicular lymphoma following high‐dose therapy and autologous stem cell transplantation	5
Baseline serum B‐cell maturation antigen levels predict time to disease progression for patients with smoldering multiple myeloma	5
Clinical outcomes following bone marrow transplantation in patients with sickle cell disease: A cohort study of US Medicaid enrollees	5
Perioperative management for patients with von Willebrand disease: Defining the optimal approach	5
First‐line therapy with bendamustine/prednisone/bortezomib—A GMMG trial for non‐transplant eligible symptomatic multiple myeloma patients	5
“Ex‐vivo” T‐cell depletion in allogeneic hematopoietic stem cell transplantation: New clinical approaches for old challenges	5
Major central nervous system complications after allogeneic stem cell transplantation: A large retrospective study on 888 consecutive adult patients	5
BAY 81‐8973 prophylaxis and pharmacokinetics in haemophilia A: Interim results from the TAURUS study	5
Identifying patients with chronic lymphocytic leukemia without need of treatment: End of endless watch and wait?	5
A nationwide study on inpatient opportunistic infections in patients with chronic lymphocytic leukemia in the pre‐ibrutinib era	5
Clinical and microbiological impact of long‐term discontinuation of fluoroquinolone prophylaxis in haematological patients with prolonged profound neutropenia	5
Post‐transplant maintenance therapy in patients with FLT3‐mutated acute myeloid leukemia: Real‐world treatment patterns and outcomes	5
Translation, validation, and usability of the International Society on Thrombosis and Haemostasis Bleeding Assessment Tool (Self‐ISTH‐BAT)	5
Long‐term tolerability of phosphodiesterase‐5 inhibitors in pulmonary hypertension of sickle cell disease	5
Carfilzomib plus dexamethasone in patients with relapsed and refractory multiple myeloma: A retro‐prospective observational study	5
Incidence of adult primary immune thrombocytopenia in England—An update	5
Validation of the Alternative International Prognostic Score‐E (AIPS‐E): Analysis of Binet stage A chronic lymphocytic leukemia patients enrolled into the O‐CLL1‐GISL protocol	5
Assessment of von Willebrand disease and pregnancy outcomes at regional Australian hospitals	5
Transfusion requirements in patients with COVID‐19	5
Immune thrombocytopenia in adults: A single‐centre review of demographics, clinical features and treatment outcomes	5
Comparison of ibrutinib and idelalisib plus rituximab in real‐life relapsed/resistant chronic lymphocytic leukemia cases	5
Circulating endothelial cells and endothelial progenitor cells as potential predictors of acute GVHD after allogeneic hematopoietic stem cell transplantation	5
Pomalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of the non‐interventional study POSEIDON and comparison with the pivotal phase 3 clinical trial	5
Incidence and socioeconomic factors in older adults with acute myeloid leukaemia: Real‐world outcomes from a population‐based cohort	5
Prevalence of non‐adherence and non‐compliance during maintenance therapy in adults with acute lymphoblastic leukemia and their associations with survival	5
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients	5
Factor VIII and IX assays for post‐infusion monitoring in hemophilia patients: Guidelines from the French BIMHO group (GFHT)	5
A phase I study of selinexor combined with weekly carfilzomib and dexamethasone in relapsed/refractory multiple myeloma	5
Evaluation of soluble fibrin monomer complex in patients in SARS‐CoV‐2 COVID‐19 infection‐associated coagulopathy	5
Predicting primary treatment failure using interim FDG‐PET scanning in diffuse large B‐cell lymphoma	5
Risk factors for invasive fungal infection in 5‐azacytidine treated patients with acute myeloid leukemia and myelodysplastic syndrome	5
Racial and ethnic differences in sickle cell disease within the United States: From demographics to outcomes	5
Clinical utility of targeted next‐generation sequencing panel in routine diagnosis of hereditary hemolytic anemia: A national reference laboratory experience	5
Life expectancy and cause of death in individuals with haemophilia A and B in Norway, 1986‐2018	5
JAK inhibition with ruxolitinib in relapsed or refractory classical Hodgkin lymphoma: Final results of a phase II, open label, multicentre clinical trial (JeRiCHO)	4
Venetoclax‐based salvage therapy for adult patients with relapsed/refractory acute lymphoblastic leukemia	4
Pixantrone in patients with relapsed/refractory diffuse large B‐cell lymphoma: A real‐life, retrospective, multicenter trial on behalf of the “RTL” (Regional Tuscan Lymphoma network)	4
Antibody titers after SARS‐CoV‐2 mRNA vaccination in patients with aplastic anemia—A single‐center study	4
Molecular classification and prognosis in younger adults with acute myeloid leukemia and intermediate‐risk cytogenetics treated or not by gemtuzumab ozogamycin: Final results of the GOELAMS/FILO acute	4
CAR‐T cell therapy in hematological malignancies: Where are we now and where are we heading for?	4
Comorbidity profile of adult survivors at 20 years following allogeneic hematopoietic cell transplantation	4
Efficacy and safety of regimens used for the treatment of multicentric Castleman disease: A systematic review	4
Standardization for obtaining blood viscosity: A systematic review	4
Mixed phenotype acute leukemia: Biological profile, clinical characteristic and treatment outcomes: Report of the population‐based study	4
Bone marrow CD3+CD56+ regulatory T lymphocytes (TR3−56 cells) are inversely associated with activation and expansion of bon	4
Immune‐related adverse events in cancer patients being treated with immune checkpoint inhibitors	4
Hematopoietic cell transplantation for Diamond Blackfan anemia: A report from the Pediatric Group of the Brazilian Bone Marrow Transplantation Society	4
Outcomes after intensive care unit admission in newly diagnosed diffuse large B‐cell lymphoma patients: A real‐life study	4
Systematic review of hematuria and acute renal failure with tranexamic acid	4
Herombopag promotes platelet engraftment and decreases platelet transfusion after allogeneic hematopoietic stem cell transplantation	4
The impact of COVID‐19 in the management of AL amyloidosis and Immunoglobulin Deposition Disease: A single‐center experience	4
Luspatercept, a two‐edged sword in beta‐thalassemia‐associated paravertebral extramedullary hematopoietic masses (EHMs)	4
Autologous stem cell transplantation vs bortezomib based chemotheraphy for the first‐line treatment of systemic light chain amyloidosis in the UK	4
Changes in body mass index during treatment of childhood acute lymphoblastic leukemia with the Nordic ALL2008 protocol	4
VEGFR2 and VEGFA polymorphisms are not associated with an inferior prognosis in Caucasian patients with aggressive B‐cell lymphoma	4
Characterization and prognostic implication of delayed complete response in AL amyloidosis	4
Systematic review of survival outcomes for relapsed or refractory adult T‐cell leukemia‐lymphoma	4
Healthcare resource utilization trends in patients with acute myeloid leukemia ineligible for intensive chemotherapy receiving first‐line systemic treatment or best supportive care: A multicenter inte	4
Histology of the spleen in immune thrombocytopenia: clinical‐pathological characterization and prognostic implications	4
Non‐driver gene mutation analysis in a large cohort of polycythemia vera and essential thrombocythemia	4
Congenital erythrocytosis	4
The evolution of immune dysfunction in multiple myeloma	4
Clinical efficacy of retreatment of daratumumab‐based therapy (D2) in daratumumab‐refractory multiple myeloma	4
Azacitidine for relapse of acute myeloid leukemia or myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation, multicenter PALG analysis	4
Patterns of previous and secondary malignancies in patients with multiple myeloma	4
Non‐myeloablative matched sibling stem cell transplantation with the optional reinforced stem cell infusion for patients with hemoglobinopathies	4
Graft‐versus‐mastocytosis effect after donor lymphocyte infusion: Proof of principle	4
Vitamin E and acute graft‐versus‐host disease after myeloablative allogeneic hematopoietic cell transplantation	4
Treatment patterns and disease course of previously untreated Primary Central Nervous System Lymphoma: Feasibility of MTX‐based regimens in clinical routine	4
Post‐transplantation erythrocytosis in kidney transplant recipients—A retrospective cohort study	4
Novel somatic alterations in unicentric and idiopathic multicentric Castleman disease	4
Long‐term tolerability and efficacy after initial PegIFN‐α addition to dasatinib in CML‐CP: Five‐year follow‐up of the NordCML007 study	4
Radiation‐free myeloablative conditioning consisting of fludarabine added to full‐dose busulfan and cyclophosphamide in single‐unit cord blood transplantation for adults	4
A regulatory element in the 3′‐untranslated region of CEBPA is associated with myeloid/NK/T‐cell leukemia	4
Prognostic models in chronic lymphocytic leukemia patients receiving ibrutinib therapy: Results of a comparative performance analysis	4
Retrospective study of treatment patterns and outcomes post‐lenalidomide for multiple myeloma in Canada	4
Anti‐thymocyte Globulin and Post‐Transplant Cyclophosphamide do not abrogate the inferior outcome risk conferred by human leukocyte antigen‐A and ‐B mismatched donors	4
IgH translocation with undefined partners is associated with superior outcome in multiple myeloma patients	4